---
document_datetime: 2023-09-21 17:43:45
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/silapo-epar-procedural-steps-taken-authorisation_en.pdf
document_name: silapo-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3770769
conversion_datetime: 2025-12-27 13:29:59.503179
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  STADA  Arzneimittel  AG  submitted  on  28  June  2006  an  application  for  Marketing Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Silapo,  through  the  centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004. The legal basis for this application refers to:

Article 10(4) of Directive 2001/83/EC, as amended - relating to applications for a biosimilar medicinal products.

The application submitted is a complete dossier:

composed of administrative information, complete quality data,  appropriate non-clinical and clinical data for a similar biological medicinal product.

## Scientific Advice:

The applicant received Scientific Advice from the CHMP on 22 March 2004 and 15 September 2005. The Scientific Advice pertained to quality, non-clinical and clinical aspects of the dossier.

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were:

Rapporteur:

Harald Enzmann

Co-Rapporteur:

Ian Hudson

## 2 Steps taken for the assessment of the product

- The application was received by the EMEA on 28 June 2006.
- The procedure started on 19 July 2006.
- The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  29 September  2006  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP members on 12 October 2007
- During the meeting on 13 - 16 November 2006, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 21 November 2006
- The applicant submitted the responses to the CHMP consolidated List of Questions on 11 May 2007.
- The Rapporteur's circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 03 July 2007
- During the CHMP meeting on 16-19 July 2007, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant
- During  the  meeting  on  15-18  October  2007,  the  CHMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation to Silapo on 18 October 2007. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 17 October 2007